
COVID-19 pandemic catalyses real-world oncology data uptake
29 July 2020
- “By necessity, COVID-19 has pushed the cancer clinical trial community out of its comfort zone to rapidly deploy remote assessments and digital health technology, [prompting] unprecedented collaboration to explore the use of real-world data. We cannot lose this opportunity to learn and advance our knowledge of the strengths and limitations of decentralized trials and real-world data to move our cancer research enterprise to a more efficient and more patient-friendly model.”
- “We’ve witnessed a great interest in taking advantage of real-world data to rapidly expand our knowledge of the natural history of disease and treatment,”
Paul G. Kleutz (Deputy Director of the Oncology Centre for Excellence, FDA)
Click here to learn more
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: JUL2020BR001